<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376763</url>
  </required_header>
  <id_info>
    <org_study_id>031-402-00129</org_study_id>
    <nct_id>NCT03376763</nct_id>
  </id_info>
  <brief_title>MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics</brief_title>
  <acronym>MAESTRO</acronym>
  <official_title>MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional, multicenter, open-label, 20 weeks study

        -  To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena.

        -  To identify efficacy and safety in switching from oral atypical antipsychotics other
           than aripiprazole to Abilify Maintena
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We would like to evaluate the efficacy and safety when switching to Abilify Maintena
      according to the approved indication of Abilify Maintena, for subjects who are taking oral
      antipsychotic drugs. It is expected that this will serve as a basis for suggesting a
      successful switching guideline from oral antipsychotics to Abilify Maintena, which can be
      applicable in clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS total score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in PANSS total score from baseline to Week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in CGI-S (severity) from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mean CGI-I (improvement) score at Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS positive and negative subscale score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in PANSS positive and negative subscale score from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IAQ score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mean IAQ score at Week 16</description>
  </secondary_outcome>
  <other_outcome>
    <measure>study discontinuation rates</measure>
    <time_frame>16 weeks</time_frame>
    <description>Comparison the study discontinuation rates between Group 1 and Group 2</description>
  </other_outcome>
  <other_outcome>
    <measure>study discontinuation rates</measure>
    <time_frame>16 weeks</time_frame>
    <description>Comparison the study discontinuation rates in Group 2 depending on the other oral atypical antipsychotics</description>
  </other_outcome>
  <other_outcome>
    <measure>proportion of subjects who have more than 20% increased rating on the PANSS total score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Comparison the proportion of subjects who have more than 20% increased rating on the PANSS total score from baseline to Week 16 between Group 1and Group 2</description>
  </other_outcome>
  <other_outcome>
    <measure>proportion of subjects who have more than 20% increased rating on the PANSS total score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Comparison the proportion of subjects who have more than 20% increased rating on the PANSS total score from baseline to Week 16 in Group 2 depending on the other oral atypical antipsychotics</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Antipsychotics</condition>
  <condition>Long-Acting Injection</condition>
  <condition>LAI</condition>
  <condition>Aripiprazole</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abilify maintena</intervention_name>
    <description>Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>long-acting injectable aripiprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be capable of providing signed and dated written informed consent by
             date of Visit 0 (-2 week).

          2. Male and female aged ≥19 and &lt; 65 years.

          3. Subjects diagnosed of schizophrenia as defined by Diagnostic and Statistical Manual of
             Mental Disorders, 4th edition text revision or 5th edition (DSM-Ⅳ-TR or 5) criteria,
             and a history of illness for at least for 3 years prior to screening.

          4. Subjects with all of the following schizophrenia clinical features:

             A. Outpatient, with no hospitalization for worsening of schizophrenia within 3 months
             prior to screening.

             B. Subjects who have no more than a moderate rating on the Positive and Negative
             Syndrome Scale (PANSS) total score≤80 C. 4 individual PANSS items which are concerning
             to psychotic symptom (P2.conceptual disorganization, P3.hallucinatory behaviour, P6.
             suspiciousness or G9. unusual thought content). score≤4.

             D. Clinical Global Impressions-Severity of Illness (CGI-S) score ≤4 (moderately ill).

          5. Subjects who take atypical antipsychotic drugs, and should be maintained on current
             antipsychotic drugs (including atypical antipsychotic drugs) and dose for at least 4
             weeks prior to the screening.

          6. Subjects who need antipsychotic treatment (other than clozapine), and would be stable
             when switching to long-acting injectable aripiprazole in the investigator's judgement.

          7. Subjects must exhibit willingness, physiologic capability, and an educational level
             sufficient to comply with all protocol procedures.

        Exclusion Criteria:

          1. Subject who showed medically significant adverse events or intolerance with
             aripiprazole during screening period or as prior experiences.

          2. Subjects with a current DSM-Ⅳ-TR or 5 diagnosis other than schizophrenia, including
             schizoaffective disorder, major depressive disorder, bipolar disorder, delirium,
             dementia, amnesia, Borderline, Paranoid, Histrionic, Schizotypal, Schizoid, Antisocial
             or other cognitive or personality disorders.

          3. Subjects with diseases of the central nervous system that may impact the assessment of
             the psychotic symptoms as per investigator's opinion.

          4. Subjects who have been treated with clozapine or long-acting injectable antipsychotic
             drugs within 3 months prior to the screening.

          5. Subjects who have been treated more than 2 oral antipsychotic drugs with the
             maintenance dose (as specified in each label) for schizophrenia treatment at
             screening.

             (e.g. Aripiprazole≥10mg/day, Olanzapine≥10mg/day, Risperidone≥2mg/day, Quetiapine
             ≥150mg/day))

          6. Subjects who have been treated over maximum maintenance dose (as specified in each
             label) of oral antipsychotics at screening. (e.g. Aripiprazole&gt;30mg/day,
             Olanzapine&gt;20mg/day, Risperidone &gt; 6mg/day, Quetiapine &gt; 750mg/day)

          7. Subjects with a significant risk of violent behaviour or a significant risk of
             committing suicide based on history or investigator's judgment.

          8. Subjects had a history of seizures, neuroleptic malignant syndrome, clinically
             significant tardive dyskinesia, or other medical condition that would expose them to
             undue risk or interfere with study assessments.

          9. Significant history of drug abuse disorder (including alcohol, as defined in DSM-5
             substance use disorder or in the opinion of the investigator) within the last 6 months
             prior to screening.

         10. Subjects participating another interventional clinical trial within 30 days prior to
             screening.

         11. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

         12. Subjects having any other clinically significant finding of the physical examination
             or laboratory value that make investigator consider that it would be inappropriate to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Soo Kwon, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heesu Kim</last_name>
    <phone>+82-2-3287-9126</phone>
    <email>heesukim@otsuka.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hae Eun Park</last_name>
    <phone>+82-2-3287-9277</phone>
    <email>hpark1116@otsuka.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Ho Choi, Dr.</last_name>
      <phone>031-560-2272</phone>
      <email>jchoi@hanyang.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si,</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eui Tae Kim, Dr.</last_name>
      <phone>031-787-7435</phone>
      <email>euitae.kim@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cha Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tai Kiu Choi, Dr.</last_name>
      <phone>031-780-5874</phone>
      <email>ctk7089@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Uijeongbu ST. Mary'S Hospital</name>
      <address>
        <city>Uijeongbu Si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyoung Uk Lee, Dr.</last_name>
      <phone>031-820-3609</phone>
      <email>mindcure@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Chul Chung, Dr.</last_name>
      <phone>063-250-2185</phone>
      <email>chungyc@jbnu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Won Jung, Dr.</last_name>
      <phone>053-250-8173</phone>
      <email>Swon12@daum.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Hee Won, Dr.</last_name>
      <phone>053-420-5751</phone>
      <email>wonsh864@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-Jin Cheon, Dr.</last_name>
      <phone>+82-53-620-3230</phone>
      <email>annemyanne@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ik Seong Chee, Dr.</last_name>
      <phone>042-280-7291</phone>
      <email>ischee@cnu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Wan Kim, Dr.</last_name>
      <phone>062-220-6148</phone>
      <email>shalompsy@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>International St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Il Ho Park, Dr.</last_name>
      <phone>+82-32-290-2825</phone>
      <email>eihpark@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong Ju Lee, Dr.</last_name>
      <phone>051-797-3305</phone>
      <email>bongjulee@empal.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Gon Kim, Dr.</last_name>
      <phone>055-360-1480</phone>
      <email>sungkim@pusan.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu Young Lee, Dr.</last_name>
      <phone>02-970-8604</phone>
      <email>lky@eulji.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo In Kim, Dr.</last_name>
      <phone>02-2650-2821</phone>
      <email>72sooik@ewha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heon Jeong Lee, Dr.</last_name>
      <phone>02-920-6721</phone>
      <email>leehjeong@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongwoo Kim, Dr.</last_name>
      <phone>+82-2-958-8196</phone>
      <email>psyjong@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hosipital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Soo Kwon, Dr.</last_name>
      <phone>+82-2-2072-2972</phone>
      <email>kwonjs@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://mfds.go.kr/index.do?mid=1769&amp;seq=12790</url>
    <description>Clinical trial guideline for Antipsychotics; Ministry Food And Drug, 2015.09.</description>
  </link>
  <link>
    <url>http://www.korea.kr/archive/expDocView.do?docId=37547</url>
    <description>The survey of Mental Disorders in Korea; Ministry of Health and Welfare, 2016</description>
  </link>
  <reference>
    <citation>Aripiprazole Investigator Brochure, Version No. 20, 16 Aug 2016</citation>
  </reference>
  <results_reference>
    <citation>Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993 Feb;50(2):85-94.</citation>
    <PMID>8427558</PMID>
  </results_reference>
  <results_reference>
    <citation>Hong Kyu Ihm et al. Factors Related to Medication Adherence in Outpatients with Schizophrenia under More Than 5 Years of Treatment. J Korean Neuropsychiatr Assoc 2016; 55(4):397-406</citation>
  </results_reference>
  <results_reference>
    <citation>Hyun-Ku Kang, et al. Safety and Effectiveness of Long Acting Injectable Antipsychotic Paliperidone Palmitate Treatment in Schizophrenics: A 24-Week Open-Label Study. Korean J Biol Psychiatry 2013;20:111-117</citation>
  </results_reference>
  <results_reference>
    <citation>Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995 Mar;52(3):173-88.</citation>
    <PMID>7872841</PMID>
  </results_reference>
  <results_reference>
    <citation>Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001 Nov;158(11):1835-42.</citation>
    <PMID>11691689</PMID>
  </results_reference>
  <results_reference>
    <citation>Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012 May;73(5):617-24. doi: 10.4088/JCP.11m07530.</citation>
    <PMID>22697189</PMID>
  </results_reference>
  <results_reference>
    <citation>Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015 Oct;168(1-2):498-504. doi: 10.1016/j.schres.2015.07.007. Epub 2015 Jul 29.</citation>
    <PMID>26232241</PMID>
  </results_reference>
  <results_reference>
    <citation>Seockhoon Chung, Chang Yoon Kim. et al. Effectiveness and Tolerability of Long-Acting Risperidone：A 12 Weeks, Multi-center Switching Study from Oral Antipsychotics. Korean J Psychopharmacol 16/2:109-120, 2005</citation>
  </results_reference>
  <results_reference>
    <citation>Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014 Aug;205(2):135-44. doi: 10.1192/bjp.bp.113.134213. Epub 2014 Jun 12.</citation>
    <PMID>24925984</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aripiprazole</keyword>
  <keyword>Long-Acting Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

